Literature DB >> 3501036

[Osteocalcin and bone histology in osteoporosis].

H Stracke1, A Schulz, U Weber, J Ullmann, H Schatz.   

Abstract

The decoupling of bone formation and bone resorption causes an insidious bone loss that is responsible for the negative skeletal balance in the frequent form of low turnover osteoporosis. The reduction of bone formation can hardly be verified by clinical methods. Osteocalcin, a non-collagenous bone protein, has proved to be a useful new indicator of bone formation. To establish its predictable value, plasma levels of osteocalcin were compared to conventional serological data of bone turnover and to histomorphometric parameters of iliac crest trabecular bone. In cases of osteoporosis with normal bone turnover activity (as confirmed by histomorphometry) no differences were observed in any of our laboratory data including osteocalcin. However, there was a significant lower mean serum level of osteocalcin in a group of patients with histomorphometrically proven low turnover osteoporosis in comparison to those with normal bone turnover. Serum levels of osteocalcin below 2.0 ng/ml seem to indicate a low turnover in the individual case of osteoporosis while this is unlikely when serum levels above 6.0 ng/ml are measured (according to our RIA).

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3501036     DOI: 10.1007/BF01736116

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  19 in total

1.  NIH Consensus Conference: osteoporosis. Factors contributing to osteoporosis.

Authors:  H Spencer; L Kramer
Journal:  J Nutr       Date:  1986-02       Impact factor: 4.798

2.  Changes in mineral content and biochemical bone markers at the menopause.

Authors:  G Mazzuoli; S Minisola; C Valtorta; R Antonelli; S Tabolli; F Bigi
Journal:  Isr J Med Sci       Date:  1985-11

3.  Prevention and therapy of osteoporosis.

Authors:  L G Raisz; J Smith
Journal:  Ration Drug Ther       Date:  1985-08

4.  [Technical improvement and application of histo-biopsy in bone marrow and bones].

Authors:  R Burkhardt
Journal:  Klin Wochenschr       Date:  1966-03-15

5.  Clinical evaluation of bone turnover by serum osteocalcin measurements in a hospital setting.

Authors:  D M Slovik; C M Gundberg; R M Neer; J B Lian
Journal:  J Clin Endocrinol Metab       Date:  1984-08       Impact factor: 5.958

6.  Assessment of bone turnover in postmenopausal osteoporosis by measurement of serum bone Gla-protein.

Authors:  P D Delmas; H W Wahner; K G Mann; B L Riggs
Journal:  J Lab Clin Med       Date:  1983-10

7.  Serum osteocalcin in the treatment of inherited rickets with 1,25-dihydroxyvitamin D3.

Authors:  C M Gundberg; D E Cole; J B Lian; T M Reade; P M Gallop
Journal:  J Clin Endocrinol Metab       Date:  1983-05       Impact factor: 5.958

8.  Short-term 1,25-dihydroxyvitamin D3 administration raises serum osteocalcin in patients with postmenopausal osteoporosis.

Authors:  J E Zerwekh; K Sakhaee; C Y Pak
Journal:  J Clin Endocrinol Metab       Date:  1985-03       Impact factor: 5.958

9.  [Osteocalcin, a marker in diseases with elevated bone metabolism].

Authors:  H Stracke; C Schatz; H Pralle; J Ullmann; H Schatz
Journal:  Dtsch Med Wochenschr       Date:  1985-09-20       Impact factor: 0.628

10.  Calcium supplements in the prevention of steroid-induced osteoporosis.

Authors:  I R Reid; H K Ibbertson
Journal:  Am J Clin Nutr       Date:  1986-08       Impact factor: 7.045

View more
  1 in total

1.  BGP (osteocalcin, bone-Gla-protein) in involutional osteoporosis.

Authors:  A Rapado; C de la Piedra; R Torres
Journal:  Clin Rheumatol       Date:  1989-06       Impact factor: 2.980

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.